Quick10K

⚲

Cell Medx

Filings

10-Q	2020-02-29	Filed 2020-04-14
10-Q	2019-11-30	Filed 2020-01-14
10-Q	2019-08-31	Filed 2019-10-15
10-K	2019-05-31	Filed 2019-09-06
10-Q	2019-02-28	Filed 2019-04-22
10-Q	2018-11-30	Filed 2019-01-14
10-Q	2018-08-31	Filed 2018-10-15
10-K	2018-05-31	Filed 2018-09-13
10-Q	2018-02-28	Filed 2018-04-16
10-Q	2017-11-30	Filed 2018-01-16
10-Q	2017-08-31	Filed 2017-10-17
10-K	2017-05-31	Filed 2017-08-29
10-Q	2017-02-28	Filed 2017-04-14
10-Q	2016-11-30	Filed 2017-01-17
10-Q	2016-08-31	Filed 2016-10-17
10-K	2016-05-31	Filed 2016-09-13
10-Q	2016-02-29	Filed 2016-04-14
10-Q	2015-11-30	Filed 2016-01-14
10-Q	2015-08-31	Filed 2015-10-15
10-K	2015-05-31	Filed 2015-09-03
10-Q	2015-02-28	Filed 2015-04-14
10-Q	2014-11-30	Filed 2015-01-14
10-Q	2014-08-31	Filed 2014-10-09
10-K	2014-05-31	Filed 2014-08-26
10-Q	2014-02-28	Filed 2014-04-18
10-Q	2013-11-30	Filed 2014-01-13
10-Q	2013-08-31	Filed 2013-10-03
10-Q	2013-02-28	Filed 2013-04-15
10-Q	2012-11-30	Filed 2013-01-16
10-Q	2012-08-31	Filed 2012-10-15
10-K	2012-05-31	Filed 2012-10-11
10-Q	2012-02-29	Filed 2012-04-09
10-Q	2011-11-30	Filed 2012-03-02
10-Q	2011-08-31	Filed 2011-10-17
10-K	2011-05-31	Filed 2011-09-21

Reports

8-K	2020-05-06	Other Events
8-K	2020-01-29	Enter Agreement, Exhibits
8-K	2019-06-24	Sale of Shares, Regulation FD, Exhibits
8-K	2019-03-21	Enter Agreement, Exhibits
8-K	2018-12-27	Enter Agreement, Sale of Shares, Exhibits
8-K	2018-05-07	Officers, Exhibits
8-K	2018-03-23	Officers, Exhibits

Cell Medx Financials

CMXC Metrics, Comps, Filings

Quarterly | Annual

Business

We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our new business direction. On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the "Subsidiary") under the laws of the Province of British Columbia.

We are a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson's disease, high blood pressure, neuropathy and kidney function. Our Subsidiary is engaged in development and manufacturing of therapeutic devices based on our proprietary eBalance Technology, which harnesses power of microcurrents and their effects on human body.

We acquired our proprietary technology for the use of microcurrents for the treatment of diabetes and related ailments, which we call eBalance Technology, on November 25, 2014, when we entered into a Technology Purchase Agreement with Jean Arnett and Bradley Hargreaves (the "Purchase Agreement").

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin


Comps ($'000 TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
Corning Natural Gas (CNIG)	73,229	70%	11.4	3%	118,609	52,954	35,540	24,990	3,124	10,059	115,115
Carbon Energy (CRBO)	72,668	95%	3.1	2%	304,504	223,025	92,326	87,934	7,340	22,227	69,154
Senomyx (SNMX)	71,057	0%		0%	21,391	7,333	26,377	0	0	0	56,357
Anchor Bancorp (ANCB)	70,950		6.8	1%	478,880	410,204	0	0	2,434	10,456	70,950
RLJ Entertainment (RLJE)	70,946	46%	-36.9	-5%	146,899	136,071	93,640	42,654	-7,438	-3,316	122,300
NutraFuels (NTFL)	70,032	48%	-29.5	-48%	5,042	2,687	3,393	1,626	-2,423	-2,366	69,824
George Risk (RSKIA)	69,554	49%	14.1	8%	43,193	3,715	14,291	7,032	3,628	4,558	64,342
Intrusion (INTZ)	69,323	61%	15.6	62%	6,764	3,494	11,071	6,732	4,169	4,305	67,212
Cell Medx (CMXC)	5,757		-6.5	-472%	191	1,963	0	0	-899	-882	5,700
Easterly Acquisition (EACQ)	68,264		22.5	2%	146,697	10,863	0	0	3,039	3,039	68,262
Poage Bankshares (PBSK)	68,196		17.6	-1%	440,728	379,510	0	0	-2,208	2,582	45,344
Omnicomm Systems (OMCM)	67,280	81%	-19.4	-44%	11,253	24,136	19,457	15,843	-4,922	-3,707	71,940
Prime Meridian Holding (PMHG)	66,178	0%	-3.7	1%	484,066	429,039	142	0	2,595	4,868	-18,100
Helix TCS (HLIX)	65,696	44%	-12.3	-12%	74,083	7,816	11,011	4,865	-8,865	-5,311	65,477
Yatra (TRTL)	65,640		-20.6	-3%	99,561	6,580	0	0	-3,178	-3,178	65,500
Vegalab (VEGL)	65,417	14%	-32.6	-22%	10,374	4,714	11,635	1,671	-2,270	-2,012	65,545
Integrity Applications (IGAP)	64,825	0%	-72.7	-44%	1,974	2,836	140	0	-874	-874	63,546
Radisys (RSYS)	64,574	27%	-97.1	-33%	57,835	65,385	109,918	29,205	-19,359	-578	56,127
Peoples Financial (PFBX)	64,261		11.4	0%	617,489	523,162	0	0	553	3,135	35,782
Electrum Special Acquisition (ELECU)	64,124		-356.8	-0%	128,485	11,837	0	0	-180	-180	64,096


Balance Sheet ($'000)	2011-08-31	2011-11-30	2012-02-29	2012-05-31	2012-08-31	2012-11-30	2013-02-28	2013-05-31	2013-08-31	2013-11-30	2014-02-28	2014-05-31	2014-08-31	2014-11-30	2015-02-28	2015-05-31	2015-08-31	2015-11-30	2016-02-29	2016-05-31	2016-08-31	2016-11-30	2017-02-28	2017-05-31	2017-08-31	2017-11-30	2018-02-28	2018-05-31	2018-11-30	2019-02-28	2019-05-31
Cash	0	0	30	24	24	19	13	11	5	2	1	1	0	0	29	1	7	2	15	28	38	118	9	67	326	108	24	8	24	131	57
Accounts Receivable
Inventory															1	1	1	1	1	5	1	4	3	8	22	29	30	11	60	64	73
PP&E																28	26	35	32	207	207	207	256	194	154	116	79		2	1	1
Assets	0	0	30	24	24	19	13	11	5	2				105	59	47	45	48	167	269	252	379	335	294	532	376	163	45	95	222	191
Accounts Payable						0	0		0	0	0	2	40	159	186	220	256	302	326	384	404	397	453	448	486	515	544	595	669	706	734
Long-Term Debt
Liabilities	7	13	17	13	13	13	13	13	13	13				393	580	731	943	1,115	1,367	1,681	1,895	880	1,107	1,463	1,563	982	1,001	1,119	1,532	1,860	1,963
Stockholders' Equity	-7	-13	13	11	11	6	-0	-2	-8	-11	-15	-20	-68	-288	-521	-684	-899	-1,067	-1,201	-1,413	-1,642	-502	-772	-1,169	-1,031	-605	-839	-1,073	-1,437	-1,638


Income Statement ($'000)	2011-08-31	2011-11-30	2012-02-29	2012-05-31	2012-08-31	2012-11-30	2013-02-28	2013-05-31	2013-08-31	2013-11-30	2014-02-28	2014-05-31	2014-08-31	2014-11-30	2015-02-28	2015-05-31	2015-08-31	2015-11-30	2016-02-29	2016-05-31	2016-08-31	2016-11-30	2017-02-28	2017-05-31	2017-08-31	2017-11-30	2018-02-28	2018-05-31	2018-11-30	2019-02-28	2019-05-31
Revenue	0	0	0	0	0	0	0	0	0	0	0	0			5								1	0
Cost of Revenue															-2								0	0
Gross Profit															3	13	1	1	1	5	2	0	0	0
R&D															146	32	554	25	16	56	73	67	53	104	48	41	111	218	34	64	15
SG&A	0	5	3	1	0	5	6	2	6	3	4	5	48		70	52	73	59	42	68	44	51	121	183	54	34	80	67	24	36	57
Tax
Net Income	-4	-6	-4	-2	0	-1	-6	-2	-6	-2	-4	-5	-48	-273	-419	-292	-1,029	-480	-296	-334	-279	-1,060	-305	394	-833	-181	-296	-236	-128	-391	-144


Cash Flow ($'000)	2011-08-31	2011-11-30	2012-02-29	2012-05-31	2012-08-31	2012-11-30	2013-02-28	2013-05-31	2013-08-31	2013-11-30	2014-02-28	2014-05-31	2014-08-31	2014-11-30	2015-02-28	2015-05-31	2015-08-31	2015-11-30	2016-02-29	2016-05-31	2016-08-31	2016-11-30	2017-02-28	2017-05-31	2017-08-31	2017-11-30	2018-02-28	2018-05-31	2018-11-30	2019-02-28	2019-05-31
Cash Operating	-2	-9	0	-7	0	-5	-6	-2	-6	-3	-1	0	-1	-20	-203	-92	-98	-65	-175	-84	-123	-280	-157	-194	-108	-225	-85	-31		-142
Cash Investing	0	0	0	0	0	0	0	0	0	0	0	0			86	-9	-19	-14	-1	-185	-15	0	-95	0						0	0
Cash Financing	2	9	30	1	0	0	0	0	0	0	0	0			145	75	122	74	186	285	149	360	142	254	366	6	0	16		250	33